GSPT1 and acute myeloid leukemia: Thalidomide analogs that degrade GSPT1 are a new class of drug that show activity against a broad range of cell lines and have recently entered early-phase clinical trials in relapsed/refractory AML with early signs of efficacy (1, 2, 32).